Abstract
Automation of proton magnetic resonance spectroscopy (MRS) in recent years has made it possible for MRS measurement to be performed in a shorter time than before, and the number of reports of its usefulness for the assessment of glioma malignancy has been increasing in the past several years. We studied the efficacy of proton MRS when used for glioma and conducted clinicopathological examination of glioma. The subjects were 15 patients who had received a pathological diagnosis of glioma at our hospital (6 cases of glioblastoma, 1 case of anaplastic astrocytoma, 4 cases of low-grade astrocytoma, and 4 cases of radiation necrosis); Siemens Magnetom Vision 1.5T was used for the study. Regions of interest (ROIs) were defined as the areas where abnormal signals were found on magnetic resonance imaging (MRI). Areas of primary peaks, such as choline (Cho),N-acetylaspartate (NAA), and lactate (Lac), were measured, and the ratios to normal brain tissue were examined. This study revealed a tendency of increased malignancy of glioma with a decrease in NAA. Some cases also displayed a decrease in Cho with an increase in malignancy. Assessment of malignancy must not be based on a single ROI alone, but several ROIs should be assessed comprehensively. Measurement was difficult when the tumor volume was small. Because diagnosis of very early glioma by MRS seemed difficult, other adjunctive diagnoses may be necessary. Proton MRS is very useful for diagnosis of glioblastoma.
Similar content being viewed by others
References
Isobe T, Matsumura A, Anno I, et al (2003) Changes in 1H-MRS in glioma patients before and after irradiation: the significance of quantitative analysis of choline-containing compounds (in Japanese) No Shinkei Geka 31:167–172
Shinoda J, Yano H, Ando H, et al (2002) Radiological response and histological changes in malignant astrocytic tumors after stereotactic radiosurgery. Brain Tumor Pathol 19:83–92
Nakaiso M, Uno M, Harada M, et al (2002) Brain abscess and glioblastoma identified by combined proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging—two case reports. Neurol Med Chir (Tokyo) 42:346–348
Law M, Yang S, Wang H, et al (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989–1998
Gajewicz W, Papierz W, Szymczak W, et al (2003) The use of proton MRS in the differential diagnosis of brain tumors and tumor-like processes. Med Sci Monit 9:MT97–105
Kuznetsov YE, Caramanos Z, Antel SB, et al (2003) Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery 53:565–574; discussion, 574–576
Nafe R, Herminghaus S, Raab P, et al (2003) Preoperative proton-MR spectroscopy of gliomas-correlation with quantitative nuclear morphology in surgical specimen. J Neurooncol 63:233–245
Nelson SJ, McKnight TR, Henry RG (2002) Characterization of untreated gliomas by magnetic resonance spectroscopic imaging. Neuroimaging Clin N Am 12:599–613
Ishimaru H, Morikawa M, Iwanaga S, et al (2001) Differentiation between high-grade glioma and metastatic brain tumor using single-voxel proton MR spectroscopy. Eur Radiol 11:1784–1791
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Izumiyama, H., Abe, T., Tanioka, D. et al. Clinicopathological examination of glioma by proton magnetic resonance spectroscopy background. Brain Tumor Pathol 21, 39–46 (2004). https://doi.org/10.1007/BF02482176
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02482176